May 19 2010
Among more than 5000 poster abstracts, Aprea AB has been selected to present a poster at the annual American Society of Clinical Oncology (ASCO) Meeting in Chicago. The presentation will describe the scientific rational and design of the ongoing phase I/II clinical trial with Aprea's drug candidate APR-246.
Aprea's drug candidate APR-246 belongs to a new class of anticancer compounds shown to induce programmed cell death through a p53 mediated mode of action. The compound is currently being tested in a phase I/II clinical trial at seven clinics in Sweden. The study will include approximately 24 patients, and is an open labeled, dose-escalating study on mainly blood cancer patients, but also patients with prostate cancer.
"We are currently initiating the commercialization process and seeking partners. Therefore, it will be very interesting to have the opportunity to present and discuss the clinical study design of this totally new concept of treating cancer", says Charlotta Liljebris, Head of Development at Aprea AB.
SOURCE Karolinska Development and Aprea
Natural compound found in olives can lower blood sugar levels and promote weight loss